Valneva (NASDAQ:VALN) Price Target Cut to $17.00 by Analysts at HC Wainwright

Valneva (NASDAQ:VALN) had its price target reduced by HC Wainwright from $18.00 to $17.00 in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Valneva Stock Performance

Shares of Valneva stock opened at $7.54 on Wednesday. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $612.70 million, a PE ratio of -58.00 and a beta of 1.98. The stock’s fifty day simple moving average is $5.10 and its 200 day simple moving average is $5.66.

Hedge Funds Weigh In On Valneva

Several institutional investors and hedge funds have recently modified their holdings of VALN. ABC Arbitrage SA bought a new position in Valneva in the fourth quarter valued at approximately $84,000. AlphaCentric Advisors LLC raised its holdings in shares of Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after acquiring an additional 29,748 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after acquiring an additional 30,859 shares in the last quarter. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.